Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070382 · ClinicalTrials.gov registry record · Phase 3
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
A Phase 3 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 14
- Enrollment target
NCT00070382 is a Phase 3 study that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 14 participants.
The verdict
NCT00070382, a Phase 3 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 14 participants
- Enrollment target
Study Summary
RATIONALE: Darbepoetin alfa and epoetin alfa may stimulate red blood cell production and treat anemia in patients who are receiving chemotherapy. It is not yet known whether darbepoetin alfa is more effective than epoetin alfa in treating patients with anemia. PURPOSE: Randomized phase III trial to compare the effectiveness of darbepoetin alfa with that of epoetin alfa in treating anemia in patients who are receiving chemotherapy for cancer.
Interventions
- DRUG darbepoetin alfa
- DRUG epoetin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2003-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00070382
The ClinicalTrials.gov registry entry for NCT00070382 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which darbepoetin alfa is the first listed.
NCT00070382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00070382 about?
NCT00070382 is a clinical study titled "Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer". RATIONALE: Darbepoetin alfa and epoetin alfa may stimulate red blood cell production and treat anemia in patients who are receiving chemotherapy. It is not yet known whether darbepoetin alfa is more effective than epoetin alfa in treating patients with anemia. PURPOSE: Randomized phase III trial to...
What is the current status of trial NCT00070382?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 14 participants. The study started on 2003-08.
What interventions are being tested in trial NCT00070382?
The interventions under investigation include: darbepoetin alfa (DRUG), epoetin alfa (DRUG).
Who is sponsoring clinical trial NCT00070382?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.